---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273899488.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock rise 1.71% to $9.50 on Tuesday, marking its second consecutive day of gains. However, it remains 53.79% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. outperformed with gains of 3.08% and 1.76%, respectively, while Viking Therapeutics Inc. experienced a decline of 1.04%. The overall market showed mixed results, with the NASDAQ up 0.91% and the Dow down 0.83%."
datetime: "2026-01-27T22:22:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273899488.md)
  - [en](https://longbridge.com/en/news/273899488.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273899488.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273899488.md) | [繁體中文](https://longbridge.com/zh-HK/news/273899488.md)


# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) rallied 1.71% to $9.50 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.91% to 23,817.10 and the Dow Jones Industrial Average falling 0.83% to 49,003.41. This was the stock's second consecutive day of gains. Corbus Pharmaceuticals Holdings Inc. closed 53.79% below its 52-week high of $20.56, which the company achieved on October 20th. The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 3.08% to $8.02, Fortress Biotech Inc. (FBIO) rose 1.76% to $3.46, and Viking Therapeutics Inc. (VKTX) fell 1.04% to $31.40. Data source: Dow Jones Market Data, FactSet. Data compiled January 27, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 01-27-26 1722ET

### Related Stocks

- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Corbus Pharmaceuticals Holdings, Inc. (CRBP.US)](https://longbridge.com/en/quote/CRBP.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Glenmark Pharmaceuticals Gets US FDA Nod for Fluticasone Propionate Inhalation Aerosol](https://longbridge.com/en/news/277723441.md)
- [Blood filter start-up, ex-executive face US charges for concealing deaths](https://longbridge.com/en/news/278137963.md)
- [Invivyd FY revenue rises; operating expenses cut sharply](https://longbridge.com/en/news/277933111.md)
- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)
- [Leo roars onto Netflix with DTC campaign for new eczema cream](https://longbridge.com/en/news/277962843.md)